MYC and cancer: The gene silencing effect of all clinically investigated siRNA nanotherapeutics is achieved through RNAi mechanism of action and the formation of RISC, except for DCR-MYC, whose RNAi mechanism targets the Dicer, which causes knockdown of many gene pathways that promote cancer proliferation and survivability, as mentioned in Figure 5.